INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29

LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the Company will be hosting a Key Opinion Leader (KOL) webinar on the topic of treatment resistant depression (TRD) at 1:00p.m. ET on Tuesday, September 29, 2020. The webinar will discuss the role of neuroinflammation in TRD and will feature presentations by two highly-regarded thought leaders in the field: Charles Raison, M.D., professor in the department of psychiatry at the University of Wisconsin at Madison, and John E. Schneider, Ph.D., chief executive officer and principal of Avalon Health Economics.

INmune Bio has recently been awarded a $2.9 million Small Business Innovation Research (SBIR) grant (which will be disbursed to the Company in stages) from the National Institutes of Health (NIH) to support a Phase 2 study of its lead clinical candidate, XPro1595, in patients with TRD.   Management will provide an overview of the trial design.

To register and access the live webinar click here or use this link:

https://zoom.us/webinar/register/WN_jBsKRkSGSF2VThn6hh5V0A

Date: September 29, 2020

Time: 1:00 PM Eastern Time

Charles Raison, M.D., professor in the department of psychiatry at the University of Wisconsin at Madison

Dr. Raison is the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families in the School of Human Ecology and a Professor in the Department of Psychiatry at the University of Wisconsin – Madison. Dr. Raison received his medical degree from Washington University in St Louis, Missouri, where he was elected to Alpha Omega Alpha and won the Missouri State Medical Association Award. He completed residency training at the UCLA Neuropsychiatric Institute and Hospital in Los Angeles. In addition to his medical training, Dr. Raison obtained his Masters of English from the University of Denver.

Dr. Raison has written and published more than 100 scientific papers as well 20 review papers and editorials. Chapters he has written have been featured in more than 30 books, and he has written two books, most recently “The New Mind-Body Science of Depression” published by WW Norton in 2017. Dr. Raison’s publications have been cited more than 14,000 times, with three publications having more than 1,000 citations. His H-index is 44. The recipient of several teaching awards, Dr. Raison has received research funding from the National Institute of Mental Health, National Center for Complementary and Alternative Medicine, and the Centers for Disease Control and Prevention. His visionary work focuses on the treatment of depression in response to illness and stress, translating neurobiological findings into novel interventions. In addition to his activities at University of Wisconsin-Madison, Dr. Raison is the mental health expert for CNN.com.